OBJECTIVES: Some studies have demonstrated that 5-aminosalicylic acid (5-ASA) is associated with a reduced risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD). However, more recent population-based studies suggest no protective association. We conducted a systematic review that focused on non-referral studies to reassess the role of 5-ASA for this indication. METHODS: We searched MEDLINE, EMBASE, and the Cochrane databases for studies of non-referral populations that assessed the association between 5-ASA use for at least 1 year and colorectal neoplasia between 1966 and 2011 and conducted a quantitative meta-analysis. RESULTS: Four observational studies fulfilled inclusion criteria. The pooled adjusted odds ratio (aOR) was 0.95 (95% confidence interval (CI): 0.66-1.38), but there was moderate heterogeneity (I2 = 58.2%; P = 0.07). A sensitivity analysis that included a fifth study in which 5-ASA use was only for a minimum of 3 months yielded a pooled aOR of 0.82 (95% CI: 0.54-1.26). A series of sensitivity analyses in which each of the four studies was excluded one at a time did not show any significant change in the overall pooled OR. We conducted a separate meta-analysis of nine clinic-based studies, which, in contrast, yielded a pooled OR of 0.58 (95% CI: 0.45-0.75). CONCLUSIONS: Our meta-analysis yielded inconsistent results that were dependent on the inclusion of either non-referral or clinic-based populations. Based on non-referral studies, there does not seem to be a protective effect of 5-ASA on CRC in IBD. However, heterogeneity among these studies limits their interpretation.
OBJECTIVES: Some studies have demonstrated that 5-aminosalicylic acid (5-ASA) is associated with a reduced risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD). However, more recent population-based studies suggest no protective association. We conducted a systematic review that focused on non-referral studies to reassess the role of 5-ASA for this indication. METHODS: We searched MEDLINE, EMBASE, and the Cochrane databases for studies of non-referral populations that assessed the association between 5-ASA use for at least 1 year and colorectal neoplasia between 1966 and 2011 and conducted a quantitative meta-analysis. RESULTS: Four observational studies fulfilled inclusion criteria. The pooled adjusted odds ratio (aOR) was 0.95 (95% confidence interval (CI): 0.66-1.38), but there was moderate heterogeneity (I2 = 58.2%; P = 0.07). A sensitivity analysis that included a fifth study in which 5-ASA use was only for a minimum of 3 months yielded a pooled aOR of 0.82 (95% CI: 0.54-1.26). A series of sensitivity analyses in which each of the four studies was excluded one at a time did not show any significant change in the overall pooled OR. We conducted a separate meta-analysis of nine clinic-based studies, which, in contrast, yielded a pooled OR of 0.58 (95% CI: 0.45-0.75). CONCLUSIONS: Our meta-analysis yielded inconsistent results that were dependent on the inclusion of either non-referral or clinic-based populations. Based on non-referral studies, there does not seem to be a protective effect of 5-ASA on CRC in IBD. However, heterogeneity among these studies limits their interpretation.
Authors: Akbar K Waljee; Ryan W Stidham; Peter D R Higgins; Sandeep Vijan; Sameer D Saini Journal: J Crohns Colitis Date: 2013-08-12 Impact factor: 9.071
Authors: Siddharth Singh; James A Proudfoot; Parambir S Dulai; Vipul Jairath; Mathurin Fumery; Ronghui Xu; Brian G Feagan; William J Sandborn Journal: Am J Gastroenterol Date: 2018-06-21 Impact factor: 10.864
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Katherine P Liao; Isaac Kohane Journal: Clin Gastroenterol Hepatol Date: 2016-02-22 Impact factor: 11.382
Authors: Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk Journal: CA Cancer J Clin Date: 2015-08-18 Impact factor: 508.702
Authors: Udayakumar Navaneethan; Ramprasad Jegadeesan; Norma G Gutierrez; Preethi G K Venkatesh; Andrea V Arrossi; Ana E Bennett; Tarun Rai; Feza H Remzi; Bo Shen; Ravi P Kiran Journal: Dig Dis Sci Date: 2013-02-01 Impact factor: 3.199